Fixed Dose Combinations for Solid Oral Drug Delivery
Rights Contact Login For More Details
- Wiley
More About This Title Fixed Dose Combinations for Solid Oral Drug Delivery
English
Outlining the steps for developing fixed dose combination (FDC) drugs, this book gives a systematic approach to the full scope of FDCs – concept, design, formulation, and commercialization.
• Includes case studies to illustrate best practices and challenges
• Deals with a growing part of the pharmaceutical industry, as FDCs are ideal for targeting many chronic illnesses and for reducing the number of medications an increasingly-aging population needs to take
• Ensures consistency in the delivery of FDC medication, which can be pivotal in increasing patient compliance and quality of life
• Collects dispersed knowledge – from patents in addition to scientific and clinical literature – so researchers can access a single source reference
• Covers regulatory guidelines from around the world and looks ahead at developing areas of personalized medicine for FDCs
• Includes case studies to illustrate best practices and challenges
• Deals with a growing part of the pharmaceutical industry, as FDCs are ideal for targeting many chronic illnesses and for reducing the number of medications an increasingly-aging population needs to take
• Ensures consistency in the delivery of FDC medication, which can be pivotal in increasing patient compliance and quality of life
• Collects dispersed knowledge – from patents in addition to scientific and clinical literature – so researchers can access a single source reference
• Covers regulatory guidelines from around the world and looks ahead at developing areas of personalized medicine for FDCs
English
Ali R. Rajabi-Siahboomi, PhD, is Vice President and Chief Scientific Officer at Colorcon. His main research interests are in the area of solid dosage form pharmaceutics and pharmaceutical technology with emphasis on oral drug delivery systems. He has published over 250 articles, book chapters, abstracts, and patents.
Amitava Mitra, PhD, works in the Biopharmaceutics group at Merck Research Labs. His main research interests include pharmacokinetics, biopharmaceutics, and modeling and simulation of oral and alternate drug delivery systems. He has published more than 20 research and review articles in peer-reviewed journals and book chapters.
Amitava Mitra, PhD, works in the Biopharmaceutics group at Merck Research Labs. His main research interests include pharmacokinetics, biopharmaceutics, and modeling and simulation of oral and alternate drug delivery systems. He has published more than 20 research and review articles in peer-reviewed journals and book chapters.
